BACKGROUND: In allergen-induced asthma, activated mast cells start the lung inflammatory process with degranulation, cytokine synthesis, and mediator release. Bruton's tyrosine kinase (Btk) activity is required for the mast cell activation during IgE-mediated secretion. METHODS: This study characterized a novel inhaled Btk inhibitor RN983 in vitro and in ovalbumin allergic mouse models of the early (EAR) and late (LAR) asthmatic response. RESULTS: RN983 potently, selectively, and reversibly inhibited the Btk enzyme. RN983 displayed functional activities in human cell-based assays in multiple cell types, inhibiting IgG production in B-cells with an IC50 of 2.5 ± 0.7 nM and PGD2 production from mast cells with an IC50 of 8.3 ± 1.1 nM. RN983 displayed similar functional activities in the allergic mouse model of asthma when delivered as a dry powder aerosol by nose-only inhalation. RN983 was less potent at inhibiting bronchoconstriction (IC50(RN983) = 59 μg/kg) than the β-agonist salbutamol (IC50(salbutamol) = 15 μg/kg) in the mouse model of the EAR. RN983 was more potent at inhibiting the antigen induced increase in pulmonary inflammation (IC50(RN983) = <3 μg/kg) than the inhaled corticosteroid budesonide (IC50(budesonide) = 27 μg/kg) in the mouse model of the LAR. CONCLUSIONS: Inhalation of aerosolized RN983 may be effective as a stand-alone asthma therapy or used in combination with inhaled steroids and β-agonists in severe asthmatics due to its potent inhibition of mast cell activation.
BACKGROUND: In allergen-induced asthma, activated mast cells start the lung inflammatory process with degranulation, cytokine synthesis, and mediator release. Bruton's tyrosine kinase (Btk) activity is required for the mast cell activation during IgE-mediated secretion. METHODS: This study characterized a novel inhaled Btk inhibitor RN983 in vitro and in ovalbuminallergicmouse models of the early (EAR) and late (LAR) asthmatic response. RESULTS:RN983 potently, selectively, and reversibly inhibited the Btk enzyme. RN983 displayed functional activities in human cell-based assays in multiple cell types, inhibiting IgG production in B-cells with an IC50 of 2.5 ± 0.7 nM and PGD2 production from mast cells with an IC50 of 8.3 ± 1.1 nM. RN983 displayed similar functional activities in the allergicmouse model of asthma when delivered as a dry powder aerosol by nose-only inhalation. RN983 was less potent at inhibiting bronchoconstriction (IC50(RN983) = 59 μg/kg) than the β-agonist salbutamol (IC50(salbutamol) = 15 μg/kg) in the mouse model of the EAR. RN983 was more potent at inhibiting the antigen induced increase in pulmonary inflammation (IC50(RN983) = <3 μg/kg) than the inhaled corticosteroid budesonide (IC50(budesonide) = 27 μg/kg) in the mouse model of the LAR. CONCLUSIONS: Inhalation of aerosolized RN983 may be effective as a stand-alone asthma therapy or used in combination with inhaled steroids and β-agonists in severe asthmatics due to its potent inhibition of mast cell activation.
Authors: Ben Forbes; Bahman Asgharian; Lea Ann Dailey; Douglas Ferguson; Per Gerde; Mark Gumbleton; Lena Gustavsson; Colin Hardy; David Hassall; Rhys Jones; Ruth Lock; Janet Maas; Tim McGovern; Gary R Pitcairn; Graham Somers; Ron K Wolff Journal: Adv Drug Deliv Rev Date: 2010-12-06 Impact factor: 15.470
Authors: David J Alexander; Christopher J Collins; Derek W Coombs; Ian S Gilkison; Colin J Hardy; Graham Healey; George Karantabias; Neil Johnson; Anna Karlsson; Joanne D Kilgour; Paddy McDonald Journal: Inhal Toxicol Date: 2008-10 Impact factor: 2.724
Authors: J V Fahy; H E Fleming; H H Wong; J T Liu; J Q Su; J Reimann; R B Fick; H A Boushey Journal: Am J Respir Crit Care Med Date: 1997-06 Impact factor: 21.405
Authors: Daigen Xu; Yong Kim; Jennifer Postelnek; Minh Diem Vu; Dong-Qing Hu; Cheng Liao; Mike Bradshaw; Jonathan Hsu; Jun Zhang; Achal Pashine; Dinesh Srinivasan; John Woods; Anita Levin; Alison O'Mahony; Timothy D Owens; Yan Lou; Ronald J Hill; Satwant Narula; Julie DeMartino; Jay S Fine Journal: J Pharmacol Exp Ther Date: 2012-01-06 Impact factor: 4.030
Authors: Yun Hao; Yan Zhao; Ping Wang; Kun Du; Ying Li; Zhen Yang; Xiangdong Wang; Luo Zhang Journal: Front Genet Date: 2021-02-02 Impact factor: 4.599